Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Cervical Cancer

December 22, 2015

Join Larissa Lee, MD and Ursula Matulonis, MD from Dana-Farber Cancer Institute as they present their multidisciplinary expertise on a range of cases pertaining to cervical cancer.

In the United States, an estimated 12,360 new cases of cervical cancer will be diagnosed, and 4020 people are expected to die of the disease. Cervical cancer rates are decreasing among women in the United States, but incidence remains high among disparate populations. Additionally, cervical cancer is the fourth-most common cancer among women worldwide; 85% of cases occur in developing countries where the disease is a leading cause of cancer death in women. Persistent human papillomavirus (HPV) infection is the most important factor in the development of cervical cancer. Prognosis for women with cervical cancer depends on the extent of disease at the time of diagnosis. Although many cases of cervical cancer can be prevented or detected early via Pap and HPV testing, a significant proportion of eligible women do not receive screening, leading to cases of difficult-to-treat advanced disease and elevated mortality rates.

The availability of new targeted therapies (i.e., bevacizumab, a VEGF-targeted antiangiogenic agent) has led to clinical trial investigation of novel combination systemic therapy regimens for treating recurrent or metastatic disease. Based on these data, the FDA recently approved bevacizumab for use in combination with cisplatin/paclitaxel or topotecan/paclitaxel regimens to treat persistent, recurrent, or metastatic cervical cancer. Treatment of early-stage cervical cancer has also evolved in recent years. Clinical data over the past decade has provided added support for the safety and efficacy of conservative treatment approaches (i.e., fertility-sparing) for treating certain patients with early-stage cervical cancer. Lastly, continual advances in imaging and minimally invasive surgical techniques present clinicians with decisions regarding an expanding array of imaging techniques and surgical approaches.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Discuss current options for the medical, radiologic, and surgical treatment of cervical cancer
  • Summarize the current and emerging clinical evidence for treating cervical cancer
Additional information

This activity is supported by educational grants from:

  • BTG
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Genomic Health, Inc.
  • Lilly
  • Merck
  • Novartis Oncology
  • Prometheus Laboratories, Inc.
  • Spectrum Pharmaceuticals, Inc.

This activity is supported by a grant from AstraZeneca.

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Course opens: 
Course expires: 
Event starts: 
12/22/2015 - 12:00pm EST
Event ends: 
12/22/2015 - 1:00pm EST

Larissa Lee, MD
Dana-Farber Cancer Institute

Ursula Matulonis, MD
Dana-Farber Cancer Institute


All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

National Comprehensive Cancer Network designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 1.0 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.

Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.


National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Type of Activity: Knowledge

National Comprehensive Cancer Network designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of continuing education credit in states that recognize ACPE accredited providers.

Universal Activity Number: 0836-0000-15-131-L01-P

Available Credit

  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing